
Prelude Therapeutics Incorporated: updates and filings
Price
$3.23
November 20, 2026Market cap $333M
What Ploutos Investor adds for Prelude Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 2 fiscal years, from 2024
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 16, 2026next Feb 11, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 16, 2026Results of operations, Regulation FD disclosureForm8-K
- Sep 10, 2026Regulation FD disclosureForm8-K
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 11, 2026Results of operationsForm8-K
- Jul 8, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 10, 2026Shareholder voteForm8-K
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 12, 2026Results of operations, Regulation FD disclosureForm8-K
- Apr 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 29, 2026Additional annual meeting materialFormDEFA14A
- Apr 29, 2026Annual meeting proxy statementFormDEF 14A
- Apr 28, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 23, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Apr 22, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Apr 21, 2026Material agreement entered, other material eventsForm8-K
- Apr 20, 2026Regulation FD disclosure, other material eventsForm8-K
- Apr 15, 2026Officer or director changeForm8-K
- Mar 12, 2026Other material eventsForm8-K
- Mar 10, 2026Shares registered for employeesFormS-8
- Mar 10, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 10, 2026Results of operations, Regulation FD disclosureForm8-K
- Feb 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 3, 2026Regulation FD disclosureForm8-K
- Jan 9, 2026Regulation FD disclosureForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 16, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Sep 10, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 11, 2026 | 8-K | Results of operations | Document |
| Jul 8, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 10, 2026 | 8-K | Shareholder vote | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 12, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Apr 29, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 29, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 29, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 28, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 23, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Apr 22, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Apr 21, 2026 | 8-K | Material agreement entered, other material events | Document |
| Apr 20, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Apr 15, 2026 | 8-K | Officer or director change | Document |
| Mar 12, 2026 | 8-K | Other material events | Document |
| Mar 10, 2026 | S-8 | Shares registered for employees | Document |
| Mar 10, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 10, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Feb 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 3, 2026 | 8-K | Regulation FD disclosure | Document |
| Jan 9, 2026 | 8-K | Regulation FD disclosure | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 11, 2016.
The full analysis
What do Prelude Therapeutics's filings show?
The filings are where every one of Prelude Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.